A nationwide register-based cohort study in Sweden, including 9,629 patients who received TNF inhibitors between 2001 and 2012, showed a double risk of invasive cervical cancer (hazard ratio, 2.10; 95% CI, 1.04 to 4.23).10 There is one Japanese case report of a 34-year-old HIV-negative patient who presented with anal cancer after three sessions of infliximab administration for Crohn disease, suggested by a rising serum concentration of carcinoembryonic antigen.11 This evidence concerns the gene CEACAM5 and cervical cancer.